Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.67 - $12.98 $19,175 - $32,450
2,500 Added 26.88%
11,800 $114,000
Q2 2024

Aug 14, 2024

SELL
$6.3 - $8.95 $47,880 - $68,020
-7,600 Reduced 44.97%
9,300 $75,000
Q1 2024

May 15, 2024

BUY
$5.26 - $10.15 $81,530 - $157,325
15,500 Added 1107.14%
16,900 $136,000
Q4 2023

Feb 14, 2024

SELL
$4.21 - $6.32 $13,893 - $20,856
-3,300 Reduced 70.21%
1,400 $7,000
Q3 2023

Nov 14, 2023

SELL
$5.14 - $11.28 $2,570 - $5,640
-500 Reduced 9.62%
4,700 $24,000
Q2 2023

Aug 14, 2023

BUY
$10.01 - $13.86 $30,030 - $41,580
3,000 Added 136.36%
5,200 $60,000
Q1 2023

May 15, 2023

BUY
$11.88 - $26.0 $26,136 - $57,200
2,200 New
2,200 $27,000

Others Institutions Holding INGN

About Inogen Inc


  • Ticker INGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 22,866,500
  • Market Cap $230M
  • Description
  • Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respirat...
More about INGN
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.